Ariad Pharma on the Top
Seite 11 von 373 Neuester Beitrag: 26.09.16 18:45 | ||||
Eröffnet am: | 17.01.14 10:56 | von: Masterbroker. | Anzahl Beiträge: | 10.311 |
Neuester Beitrag: | 26.09.16 18:45 | von: Masterbroker. | Leser gesamt: | 1.311.900 |
Forum: | Börse | Leser heute: | 560 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 8 | 9 | 10 | | 12 | 13 | 14 | ... 373 > |
krebs wird hoffentlich irgendwann den schrecken verlieren.
und aria in der kommenden woche neue märkte melden.
das wär doch was, oder?
LOL Fusion ;-) Naja heute dewegen mal was ausruhen Morgen gehts dann wieder zur Sache mit unsern USA Boys and Girls
Dann wird sie drehen aber ob wir genug Schubkraft haben für einen "größeren" Kursanstieg mag ich aktuell nicht glauben.
Was sagt ihr?
wie man sehen kann im Blauem kasten für den 24 Jan sind kaum nennenswerte Put´s ;-) das ist schon mal sehr gut.Ich rechne heute mit steigenden Kursen alleine weil am FR so stark ge Shortet wurde auf Hammer News
Naja. Ist doch aber auch super für diejenigen die richtig Geld verdienen wollen. Trotz aller erreichten Milestones beginnt der Kurs wieder unten! Ist doch für die meisten super! Für mich leider nicht so, obwohl ich noch dick im Plus bin. Mir wäre der starke und schnelle Anstieg 10x lieber!
http://wallstreetpr.com/...hopes-high-again-withiclusigs-return-13722
posted on Jan 21 2014 - 8:30am by Karthikeyan Narayanan
Boston, MA 01/21/2013 (wallstreetpr) – Finally, after all the regulatory hurdles, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) puts its Iclusig back into markets in the United States. Slowly, but steadily, the bleeding bio-tech firm is regaining its lost ground as it came nearly 3% up to $6.90.
Safety Concerns Disturbed The Strong Story
The year 2013 was harsh on Ariad investors as the company’s stocks plummeted following a red flag raised by the FDA for its cancer drug Iclusig. Formerly, Iclusig had been approved by the FDA in December 2012 to treat patients with medical conditions of chronic myeloid leukemia. After the approval, the stocks of the company scaled new heights of as close as 850%, in the last five years, however, reports of side-effect, including blood clot and increased probability of heart damage,led the FDA to ask Ariad to stop marketing of Iclusig.
The FDA decision also resulted in safety reviews of Iclusig conducted in European markets as well. But, the EMA’s decision to keep Iclusig in markets with added warning labels came as a rescue to Ariad, which was expecting a sequential blow. The company also stayed afloat through enormous workforce and cost reductions, to balance the sudden loss in revenues.
Nothing More Than Iclusig
Except Iclusig’s ban, the company’s other weaknesses also played a role in its crash. The factors like absence of pipeline of competitive drugs, a negative operating cash flow of $21 million and lower revenue numbers in first three quarters of the financial year 2013, all led to its downfall. Ariad had reported a meager $37 million revenues in the year 2013.
But, as the year 2014 unfolds with brighter prospects for Ariad, the chances are high for the company to grow tremendously ahead. After the October fall, the stock prices have approximately tripled, indicating more growth, but the rest depends on how successful Iclusig gets in its second term.